[1] Chakraborty AK. Epidemiology of tuberculosis: current status in India. Indian journal of medical research. 2004;120(4):248-76.
[2] Udwadia ZF, Mehra C. Tuberculosis in India. BMJ. 2015;350. https://doi.org/10.1136/bmj.h1080.
[3] Law S. Exploring TB patient journeys and the emergence of MDR-TB in India and South Africa: A multi-methods study. McGill University (Canada); 2019;28248042.
[4] Satyanarayana S, Nair SA, Chadha SS, Shivashankar R, Sharma G, Yadav S, et al. From where are tuberculosis patients accessing treatment in India? Results from a cross-sectional community based survey of 30 districts. PloS one. 2011;6(9):e24160. https://doi.org/10.1371/journal.pone.0024160.
[5] Chauhan LS, Arora VK. Management of pediatric tuberculosis under the Revised National Tuberculosis Control Program (RNTCP). Indian Pediatr. 2004;41(9):901-5.
[6] Yang C, Luo T, Shen X, Wu J, Gan M, Xu P, et al. Transmission of multidrug-resistant Mycobacterium tuberculosis in Shanghai, China: a retrospective observational study using whole-genome sequencing and epidemiological investigation. The Lancet Infectious Diseases. 2017;17(3):275-84. https://doi.org/10.1016/S1473-3099(16)30418-2.
[7] Seung KJ, Keshavjee S, Rich ML. Cold Spring Harbor Perspect. Med. 2015;5(9):a017863.
[8] Hirpa S, Medhin G, Girma B, Melese M, Mekonen A, Suarez P, et al. Determinants of multidrug-resistant tuberculosis in patients who underwent first-line treatment in Addis Ababa: a case control study. BMC Public Health. 2013;13:1-9. https://doi.org/10.1186/1471-2458-13-782.
[9] Fikre A, Tewelde T, Shaweno T. Determinants of multi-drug resistant tuberculosis among tuberculosis patients in Southern Ethiopia: a case control study. Journal of Medical Bacteriology. 2019;8(1-2):1-12.
[10] Admassu F, Abera E, Gizachew A, Sedoro T, Gari T. Risk factors of multidrug resistant tuberculosis among patients with tuberculosis at selected multidrug resistance treatment initiative centres in southernEthiopia: a case-control study. BMJ open. 2023;13(1):e061836. http://dx.doi.org/10.1136/bmjopen-2022-061836.
[11] Oga-Omenka C, Tseja-Akinrin A, Sen P, Mac-Seing M, Agbaje A, Menzies D, et al. Factors influencing diagnosis and treatment initiation for multidrug-resistant/rifampicin-resistant tuberculosis in six sub-Saharan African countries: a mixed-methods systematic review. BMJ global health. 2020;5(7):e002280. http://dx.doi.org/10.1136/bmjgh-2019-002280.
[12] Chowdhury K, Ahmad R, Sinha S, Dutta S, Haque M. Multidrug-Resistant TB (MDR-TB) and Extensively Drug-Resistant TB (XDR-TB) Among Children: Where We Stand Now. Cureus. 2023;15(2):e35154. https://doi.org/10.7759/cureus.35154.